The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years weighing 45 kg or more, expanding its use beyond adults.
As Trump’s health officials push personal responsibility, critics warn their rhetoric blames patients, shapes policy, and risks deepening health inequalities.
As neurotech devices move from clinics to consumers, states are racing to safeguard brainwave data from earbuds, sleep trackers, and AI-powered apps—raising new questions about privacy, consent, and medical ethics.
HHS unexpectedly canceled a meeting of the U.S. Preventive Services Task Force, prompting fears it may be dismantled following similar moves by Secretary Robert F. Kennedy Jr. at other federal health agencies.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.
The USPSTF's draft recommendations reaffirm osteoporosis screening for older women, call for more research on screening men, and address health disparities.
Indivior, a Virginia-based drug manufacturer, has reached an $86 million settlement with 16 U.S. states over its alleged role in the opioid addiction crisis, involving buprenorphine-based products. The settlement funds will be used for opioid addiction treatment, recovery, and prevention.